HRMY · Harmony Biosciences Holdings, Inc. · Investor Relations
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-10-20 |
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
PLYMOUTH MEETING, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, before the open of the U.S. financial markets. |
| 2026-10-12 |
Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
The Board of Directors has appointed Peter Anastasiou, former Harmony board member and current Sr. EVP and COO, to become President, Chief Executive Officer and a member of the Board, effective January 1, 2027. Current CEO Jeffrey M. Dayno, M.D., will retire at the end of the year following a |
| 2026-10-01 |
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. |
| 2026-09-22 |
Harmony Biosciences Recognizes World Narcolepsy Day 2026, Reflecting on Nearly a Decade of Commitment to the Sleep Community
PLYMOUTH MEETING, Pa. -- Sept. 22, 2026 -- Harmony Biosciences today recognized World Narcolepsy Day, observed annually on September 22, by reflecting on nearly a decade of commitment to the narcolepsy and broader sleep-wake community. Since its founding in 2017, Harmony has worked alongside |
| 2026-09-03 |
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company’s investigation of EPX-100 (clemizole hydrochloride) at the 16 th European Epilepsy Congress being held from September 5-9, |
| 2026-08-27 |
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 |
| 2026-08-06 |
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET. |
| 2026-08-04 |
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 Billion Phase 1 SAD Data for BP-205 Demonstrate Favorable PK and Safety/Tolerability Profiles; |
| 2026-07-21 |
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, before the open of the U.S. financial markets. |
| 2026-07-16 |
Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition
WAKIX® Net Revenue Grew 30% Year over Year to a Record of Approximately $261 Million for Q2 2026 Reaffirms 2026 Net Revenue Guidance of $1.0 Billion to $1.04 Billion Full Q2 2026 Financial Results and Business Updates to be Reported on August 4, 2026 PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Jul. |
| 2026-06-11 |
Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Jun. 11, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that six abstracts in narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at SLEEP 2026, the 40th annual meeting of the Associated Professional |
| 2026-05-27 |
Harmony Biosciences to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--May 27, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat: June 9, |
| 2026-05-07 |
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion Continue to Vigorously Protect WAKIX IP into 2030; Filed Suit Against AET Pharma/Sandoz Regarding Infringement of Amorphous Pitolisant Patent Lifecycle Management Advancing |
| 2026-04-23 |
Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Apr. 23, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. |
| 2026-04-16 |
Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting
PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Apr. 16, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore open-label extension data from the company’s investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment |
| 2026-04-14 |
Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer
COMPANY REITERATES ITS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION IN WAKIX SALES PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Apr. 14, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, |
| 2026-04-02 |
Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board
Appointments support Harmony’s next phase of growth and long‑term value creation PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Apr. 2, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of |
| 2026-03-31 |
Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference
PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Mar. 31, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that Harmony's management team will participate in a fireside chat at the upcoming 25 th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026, at 9:30 a.m. |
| 2026-03-04 |
Harmony Biosciences to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Mar. 4, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will attend the following upcoming investor conferences. Leerink Partners Global Healthcare Conference Date: March 9, 2026 Location: Miami, FL |
| 2026-02-24 |
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy Recently Completed Settlements with 3 Additional Generic Filers Toward Goal of Securing WAKIX Franchise Pitolisant GR NDA Submission on Track for Q2 2026; |